Lenexa, Kansas – Harbor Healthcare is pleased to announce the sale of Midwest Compounders, a 503A sterile compounding pharmacy based in Lenexa, Kansas, to a strategic healthcare investor recognized for deep industry expertise and national relationships.
The compounding pharmacy segment has experienced rapid growth over the past decade as integrative medicine has gained recognition and innovative therapies have entered the market. While consolidation has accelerated, the sector remains fragmented, presenting attractive M&A opportunities for independent owners and acquirers. This transaction reflects the growing trend of aligning independent pharmacies with partners that can provide scale, compliance infrastructure, and expanded patient reach.
Founded and operated for more than two decades under the leadership of Troy DeLong, Midwest Compounders has established itself as a trusted partner to patients and providers across the region. As part of the acquisition, a new CEO was recruited, allowing Troy to focus on the areas of the business he thrives on most.
“This partnership gives Midwest Compounders the resources and reach to expand nationally, while preserving the patient-first culture we’ve built over 20 years.” said Troy DeLong. “I’m excited to continue leading our pharmacy operations and contribute to this new team while we accelerate our momentum and scale the business nationwide.”
“Midwest Compounders built a reputation for precision, service, and trust in the compounding pharmacy sector,” said Dan Riley, CEO of Midwest Compounders. “With the support of our new strategic partner and the foundation Troy built over the past 20 years, we are poised to scale rapidly, broaden our therapies, and set a new standard for compounding pharmacy nationwide.”
“It was an honor to represent Troy and Midwest Compounders in this transaction.” Said Mark Alford, Managing Director at Harbor Healthcare. “We identified a partner whose strategic vision, commitment to compliance, and industry relationships uniquely position the company to grow while honoring its legacy. This is an unprecedented time for compounding pharmacy, and this transaction shows the importance of choosing a partner who understands both valuation and legacy. In today’s consolidating pharmacy market, owners have a unique opportunity to capture full value and secure the right future for their businesses.”
Harbor Healthcare served as the exclusive sell-side advisor to Midwest Compounders.
About Midwest Compounders
Midwest Compounders is a sterile 503A compounding pharmacy headquartered in Lenexa, Kansas and licensed in multiple states. The company specializes in integrative therapies with an emphasis on quality, safety, compliance and exceptional customer service.
About Harbor Healthcare Consultants
Harbor Healthcare is a boutique M&A advisory firm offering advisory services to middle market healthcare organizations and specializing in compounding pharmacy since 1995. The company provides perceptive strategic solutions to independent owners and investors of long-term care, specialty, home infusion, compounding (503A and 503B) and 340B pharmacies. A pharmacist-founded firm comprised of bankers and healthcare entrepreneurs, Harbor offers unparalleled regulatory and advisory expertise while maintaining unshakeable business relationships with strategic, private equity and independent acquirers.
For more information, please contact Mark Alford, Managing Director at Harbor Healthcare (619) 535-9005 or visit https://www.harborhealthcare.com.
Click Here for a Sample of Our M&A Transactions
Select Transactions